newsfilter
← Latest News
GlobeNewswire·

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar's Potential to Convert ‘Cold'